Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

842
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
842
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

738
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
738
Pharmacovigilance01:19

Pharmacovigilance

983
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
983

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Tradipitant: First Approval.

Drugs·2026
Same author

Depemokimab: First Approval.

Drugs·2026
Same author

Sibeprenlimab: First Approval.

Drugs·2026
Same author

Zongertinib: First Approval.

Drugs·2026
Same author

Rilzabrutinib: First Approval.

Drugs·2025
Same author

Dorocubicel: First Approval.

Molecular diagnosis & therapy·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
関連記事をすべて見る

関連する実験動画

Updated: Sep 9, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.4K

リンボセルタマブ:最初の承認

Arnold Lee1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|August 29, 2025
PubMed
まとめ
この要約は機械生成です。

リンボセルタマブ (BCMAとCD3を標的とする双特定抗体) は,再発性/耐性多発性骨髄腫の治療にEUで承認されました. これは,進行した血液がんの T細胞治療の進歩における重要なマイルストーンです.

さらに関連する動画

Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS

Published on: October 7, 2009

27.2K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K

関連する実験動画

Last Updated: Sep 9, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.4K
Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS

Published on: October 7, 2009

27.2K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K

科学分野:

  • 腫瘍学
  • 免疫学
  • 薬理学について

背景:

  • 多発性骨髄腫は血性悪性腫瘍で,血細胞の制御不能な増殖が特徴です.
  • 再発性/耐性多発性骨髄腫は,多くの場合,新しい治療戦略を必要とする,重要な満たされていない医療ニーズを示しています.
  • B細胞成熟抗原 (BCMA) は多発性骨髄腫における有効な標的である.

研究 の 目的:

  • リンボセルタマブの重要な発達のマイルストーンを要約します.
  • リンボセルタマブの欧州連合での規制承認を強調する.
  • リンボセルタマブの作用のメカニズムと指示の概要

主な方法:

  • リンボセルタマブは,BCMAが悪性B細胞に結合し,CD3がT細胞に結合するように設計されたバイスペシフィック抗体です.
  • この二重結合は,BCMA発現する腫瘍細胞を T細胞に誘導し,排除する.
  • 開発のマイルストーンには,臨床前試験,臨床試験,規制当局への提出が含まれます.

主要な成果:

  • リンボセルタマブは2025年4月28日にEUで最初の販売許可を取得しました.
  • この承認は,再発性/耐性多発性骨髄腫の成人の単体治療に使用するものです.
  • 患者は,特定の薬剤を含む少なくとも3つの以前の治療を受け,疾患の進行を示した必要があります.

結論:

  • リンボセルタマブは,重度の多発性骨髄腫の治療前の患者にとって新しい治療法です.
  • このEU承認は,BCMA誘導免疫療法における大きな進歩を意味しています.
  • このマイルストーンは,血液学的悪性腫瘍の治療における双特定抗体の可能性を強調しています.